Sionna Therapeutics, Inc. reported topline results from its PreciSION CF Phase 2a trial on August 10, 2026, including a primary endpoint miss, and said it would not advance SION-719 as an add-on to standard of care. The company’s shares fell $46.54, or 91.2%, to close at $4.10 on August 10. Glancy Prongay Wolke & Rotter LLP said on August 26 that it was continuing an investigation into possible federal securities-law violations on behalf of investors. The firm is seeking investors who lost money or possess relevant non-public information and noted that eligible SEC whistleblowers may receive up to 30% of a successful recovery. An earlier version of the topic identified the Law Offices of Frank R. Cruz, while a prior version had identified the Law Offices of Howard G. Smith.